Radboud University Medical Center autologous dendritic cell vaccine

The Radboud University Medical Center autologous dendritic cell vaccine is a cell-based cancer immunotherapy developed for the treatment of melanoma. The vaccine is produced by isolating a patient's own dendritic cells (DCs) or their precursors (such as monocytes) from the blood, maturing them ex vivo, and loading them with specific tumor-associated antigens, primarily tyrosinase and gp100 (melanocyte protein PMEL). Once re-infused into the patient—often via intranodal or intradermal injection—these mature, antigen-loaded DCs act as professional antigen-presenting cells that prime and activate the patient's T cells to recognize and eliminate melanoma cells. Radboud University has investigated various formulations of this vaccine, including those derived from monocytes (moDCs) and naturally circulating subsets like CD1c+ myeloid DCs and plasmacytoid DCs (pDCs). Clinical development has spanned both the adjuvant setting (Stage III) and the metastatic setting (Stage IV), sometimes exploring combinations with immune-modulating agents like Daclizumab to deplete regulatory T cells.

Other names

Radboudumc dendritic cell vaccineTyrosinase and gp100-loaded dendritic cell vaccinedendritic cells-Radboud University Medical Center-melanoma